Literature DB >> 9460973

Sensory nerves in the interface membrane of aseptic loose hip prostheses.

M Ahmed1, J Bergström, H Lundblad, W J Gillespie, A Kreicbergs.   

Abstract

We studied the presence of sensory nerves by immunohistochemistry in the interface membranes of hip prostheses after aseptic loosening. Substance P (SP), neurokinin A (NKA) and calcitonin gene-related peptide (CGRP) were analysed as was protein gene product (PGP) 9.5, a general marker for nerve fibres. We identified nerve fibres in all samples but differences in their density were found. SP- and NKA-positive fibres were predominantly non-vascular, forming varicose nerve terminals. CGRP-immunoreactive nerve fibres with varicose terminals were seen mostly close to blood vessels, but also as free nerve endings. Sensory neuropeptides participate not only in nociception but also stimulate immune cells to release cytokines. The presence of sensory nerves in the interface membrane may reflect a pathophysiological response contributing to the aseptic loosening of hip prostheses.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9460973     DOI: 10.1302/0301-620x.80b1.8138

Source DB:  PubMed          Journal:  J Bone Joint Surg Br        ISSN: 0301-620X


  11 in total

Review 1.  [Patellofemoral pain].

Authors:  V Sanchis-Alfonso
Journal:  Orthopade       Date:  2008-09       Impact factor: 1.087

Review 2.  Periprosthetic osteolysis: genetics, mechanisms and potential therapeutic interventions.

Authors:  Shahryar Noordin; Bassam Masri
Journal:  Can J Surg       Date:  2012-12       Impact factor: 2.089

3.  Intraarticular botulinum toxin A for refractory painful total knee arthroplasty: a randomized controlled trial.

Authors:  Jasvinder A Singh; Maren L Mahowald; Siamak Noorbaloochi
Journal:  J Rheumatol       Date:  2010-09-01       Impact factor: 4.666

4.  Alpha-calcitonin gene-related peptide can reverse the catabolic influence of UHMWPE particles on RANKL expression in primary human osteoblasts.

Authors:  Max D Kauther; Jie Xu; Christian Wedemeyer
Journal:  Int J Biol Sci       Date:  2010-09-15       Impact factor: 6.580

5.  Effects of alpha-calcitonin gene-related peptide on osteoprotegerin and receptor activator of nuclear factor-κB ligand expression in MG-63 osteoblast-like cells exposed to polyethylene particles.

Authors:  Jie Xu; Max D Kauther; Julia Hartl; Christian Wedemeyer
Journal:  J Orthop Surg Res       Date:  2010-11-04       Impact factor: 2.359

6.  Calcitonin substitution in calcitonin deficiency reduces particle-induced osteolysis.

Authors:  Max D Kauther; Hagen S Bachmann; Laura Neuerburg; Martina Broecker-Preuss; Gero Hilken; Florian Grabellus; Gabriele Koehler; Marius von Knoch; Christian Wedemeyer
Journal:  BMC Musculoskelet Disord       Date:  2011-08-15       Impact factor: 2.362

7.  Efficacy of Long-term Effect and Repeat Intraarticular Botulinum toxin in Patients with Painful Total Joint Arthroplasty: A Retrospective Study.

Authors:  Jasvinder A Singh
Journal:  Br J Med Med Res       Date:  2014-01

8.  Cytokine and neuropeptide levels are associated with pain relief in patients with chronically painful total knee arthroplasty: a pilot study.

Authors:  Jasvinder A Singh; Siamak Noorbaloochi; Keith L Knutson
Journal:  BMC Musculoskelet Disord       Date:  2017-01-14       Impact factor: 2.362

9.  Immune response and innervation signatures in aseptic hip implant loosening.

Authors:  Daniel M Vasconcelos; Manuel Ribeiro-da-Silva; António Mateus; Cecília Juliana Alves; Gil Costa Machado; Joana Machado-Santos; Diogo Paramos-de-Carvalho; Inês S Alencastre; Rui Henrique; Gilberto Costa; Mário A Barbosa; Meriem Lamghari
Journal:  J Transl Med       Date:  2016-07-07       Impact factor: 5.531

10.  No Association of CALCA Polymorphisms and Aseptic Loosening after Primary Total Hip Arthroplasty.

Authors:  Tünay Aydin-Yüce; Gina Kurscheid; Hagen Sjard Bachmann; Thorsten Gehrke; Marcel Dudda; Markus Jäger; Christian Wedemeyer; Max Daniel Kauther
Journal:  Biomed Res Int       Date:  2018-06-05       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.